Table 2. Effect of anti-CD9 antibodies and CD9 knockdown on formation of breast cancer/MSC hybrids.
| MDA/MSC | % hybrids ± S.D.1 | P value |
|---|---|---|
| Control | 0.68 ± 0.16 | |
| Anti-CD9 (MEM-61) | 0.15 ± 0.10 | 0.007 |
| Anti-CD9 (M-L 13) | 0.184 ± 0.16 | 0.016 |
| Anti-CD9 (P1/33/2) | 0.5 ± 0 | 0.11 |
| CD9 knockdown | 0 | 0.0018 |
| MA-11/MSC | ||
| Control | 0.12 ± 0.05 | |
| CD9 knockdown | 0 | 0.022 |
| MCF-7/MSC | ||
| Control | 0 | |
| CD9 knockdown | 0 | |
| HuMEC/MSC | ||
| Control | 0 |
1
2000 BCCs and 8000 MSCs were plated together (24-well plate) and dual fluorescence of heterotypic hybrids was counted after 6 days of co-cultures. The percentage of hybrids was calculated relative to the initial number of BCCs. Data are the mean of five independent experiments. Anti-CD9 Ab clone is indicated in bracket.